内部人士在公司亏损,试验成功和资金增加的情况下出售股票. Insider sold shares amid company loss, trial success, and funding boost.

2026年3月13日, Xenon制药公司(NASDAQ:XENE)一名内幕人士以55.23美元出售了1 342股股票,所有权减少了15.53%,而CEO Ian Mortimer先前出售了7 308股股票。 On March 13, 2026, an insider at Xenon Pharmaceuticals (NASDAQ:XENE) sold 1,342 shares at $55.23, reducing ownership by 15.53%, while CEO Ian Mortimer previously sold 7,308 shares. 该公司报告了每股1.31美元的Q4损失,缺少估计数,分析师预测全年损失3.10美元。 The company reported a Q4 loss of $1.31 per share, missing estimates, and analysts project a full-year loss of $3.10. 尽管如此,对癫痫XEN1101 (azetukalner)的第三阶段X-TOLE2试验已经完成,支持了计划提出的国家药物管理局文件。 Despite this, the Phase 3 X-TOLE2 trial for XEN1101 (azetukalner) in epilepsy was completed, supporting a planned NDA filing. 价值7.475亿美元的大规模公开发行扩大了现金跑道,机构所有权增加到95.45%。 A $747.5 million upsized public offering extended the cash runway, and institutional ownership rose to 95.45%. 库存以55.23美元关闭,数量增加,分析师维持协商一致的“Buy”评级,目标为71.94美元,虽然内部销售引起了投资者的关切。 The stock closed at $55.23 with elevated volume, and analysts maintain a consensus “Buy” rating with a $71.94 target, though insider sales have raised investor concerns.